{"id":5710,"date":"2016-08-19T15:00:32","date_gmt":"2016-08-19T13:00:32","guid":{"rendered":"https:\/\/www.institut-biotherapies.fr\/en\/?page_id=5710"},"modified":"2016-08-19T15:00:32","modified_gmt":"2016-08-19T13:00:32","slug":"hereditary-inclusion-body-myopathy","status":"publish","type":"page","link":"https:\/\/www.institut-biotherapies.fr\/en\/muscle-diseases\/hereditary-inclusion-body-myopathy\/","title":{"rendered":"Hereditary Inclusion Body Myopathy"},"content":{"rendered":"<p>Hereditary inclusion body myopathy (HIBM) is a severe progressive myopathy\u00a0affecting a weakness in lower limb distal muscles, generally during early adulthood, leading to a loss of\u00a0muscular strength and function and, in the long run, to the loss of walking ability. The virulence of the disease is progressive and varies from a duration of 10 to 20 years or more.<\/p>\n<p>&nbsp;<\/p>\n<h2>ClinBio-GNE study<\/h2>\n<ul>\n<li><strong>Reference laboratory:\u00a0<\/strong>Institute of Myology<\/li>\n<\/ul>\n<p>ClinBio-GNE&#8217;s aim is to study clinical and biological endpoints for hereditary inclusion body myopathies due to the mutation of gene GNE.<\/p>\n<h2>HIBM-PMP study<\/h2>\n<ul>\n<li><strong>Reference laboratory:\u00a0<\/strong>Institute of Myology<\/li>\n<\/ul>\n<p>This registry and prospective observational natural history study aims at assessing GNE myopathy or hereditary inclusion body myopathy (HIBM).<\/p>\n<p>For further information: <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01784679\" target=\"_blank\">HIBM-PMP study webpage<\/a><\/p>\n<h2>HIBM Phase III trial\u00a0\u2014 UX001-CL301<\/h2>\n<ul>\n<li><strong>Reference laboratory:<\/strong> Institute of Myology<\/li>\n<\/ul>\n<p>This phase III randomized, double-blind, placebo-controlled study aims at evaluating the efficacy and safety of Sialic acid extended-release tablets in patients with GNE myopathy or hereditary inclusion body myopathy (HIBM).<\/p>\n<p>For further information: <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02377921\" target=\"_blank\">HIBM Phase III trial webpage<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hereditary inclusion body myopathy (HIBM) is a severe progressive myopathy\u00a0affecting a weakness in lower limb distal muscles, generally during early adulthood, leading to a loss of\u00a0muscular strength and function and, in the long run, to the loss of walking ability. The virulence of the disease is progressive and varies from a duration of 10 to &hellip; <a href=\"https:\/\/www.institut-biotherapies.fr\/en\/muscle-diseases\/hereditary-inclusion-body-myopathy\/\">[Read more]<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"parent":4283,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-5710","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/pages\/5710","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/comments?post=5710"}],"version-history":[{"count":1,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/pages\/5710\/revisions"}],"predecessor-version":[{"id":5711,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/pages\/5710\/revisions\/5711"}],"up":[{"embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/pages\/4283"}],"wp:attachment":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/media?parent=5710"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}